New Hampshire Can Stop Runaway Prescription Drug Costs – Here’s How to Make It Happen

Tell your lawmakers to support legislation reestablishing a Prescription Drug Affordability Board this legislative season

Quick Context

Drug manufacturers set prices as high as the market will bear – that’s why Americans pay 2-4 times what patients in other countries pay for the same medications. Eleven states have already established Drug Price Accountability Boards, or what some states call a Prescription Drug Affordability Board. New Hampshire was one and should stand for patients and families once again. This is a commonsense way to address affordability issues in our state.

Where New Hampshire Stands

New Hampshire had a Drug Price Accountability Board. Now is the time to restore it.

Legislation reestablishing a Prescription Drug Affordability Board could be introduced this legislative season – but only if lawmakers hear from constituents that this matters.

Take Action: Contact Your Legislators

Your voice makes a difference. Tell your New Hampshire state lawmakers to support legislation reestablishing a Prescription Drug Affordability Board.

Why This Matters to NEW HAMPSHIRITES

1 in 4 adults report difficulty affording prescription medications

New Hampshire taxpayers spend an average of $83M a year on Medicaid prescription drugs, even after manufacturer rebates – based on the three most recent years of data (FY2021–2023). Driven by manufacturers’ list prices, these costs strain state budgets, taxpayers, and small businesses.

Four states can now set Upper Payment Limits on unaffordable medications – power to be used only in extreme cases of runaway drug prices, causing harm to our state’s residents. New Hampshire could be the fifth.

What Happens Next

✓ Your message will be delivered to your lawmakers

✓ We’ll keep you updated on New Hampshire drug price accountability and affordability legislation

✓ Your voice joins other New Hampshirites calling for drug price reform

Recent Momentum

Colorado became the first state to vote for a drug price cap in February 2024, targeting Enbrel (a medication for autoimmune diseases, like rheumatoid arthritis) after its price increased 1,582% since FDA approval. New Hampshire has the opportunity to take a stand this legislative season.